Type III protein secretion systems, which are organelles with the capacity to deliver bacterial proteins into host cells, have been adapted to deliver heterologous antigens for vaccine development. A limitation of these antigen delivery systems is that some proteins are not amenable to secretion through this pathway. We show here that proteins from the simian and human immunodeficiency viruses that are not permissive for secretion through a Salmonella enterica serovar Typhimurium type III secretion system can be modified to travel this secretion pathway by introduction of discrete mutations. Proteins optimized for secretion were presented more efficiently via the major histocompatibility complex class I pathway and were able to induce a better immune response.
Type III protein secretion systems, which are organelles with the capacity to deliver bacterial proteins into host cells, have been adapted to deliver heterologous antigens for vaccine development. A limitation of these antigen delivery systems is that some proteins are not amenable to secretion through this pathway. We show here that proteins from the simian and human immunodeficiency viruses that are not permissive for secretion through a Salmonella enterica serovar Typhimurium type III secretion system can be modified to travel this secretion pathway by introduction of discrete mutations. Proteins optimized for secretion were presented more efficiently via the major histocompatibility complex class I pathway and were able to induce a better immune response.
Avirulent strains of Salmonella enterica serovar Typhimurium are being considered as antigen delivery vectors for heterologous vaccine development (8, 19, 27, 40) . The availability of several virulence-attenuating mutations and the ease with which Salmonella can be genetically manipulated, coupled with its intrinsic ability to stimulate the innate immune system, have made Salmonella a very promising platform for the construction of vaccines to protect against a variety of infectious diseases or even cancer. Thus, Salmonella vaccine strains endowed with the capacity to express heterologous antigens have been constructed and tested in a variety of animal models and human volunteers (3, 10, 19, 21, 33, 40, 45) . A limitation in the use of Salmonella as a vaccine platform, however, has been its apparent inefficiency at stimulating major histocompatibility complex (MHC) class I-restricted CD8 ϩ (cytotoxic) T-cell responses (18, 36, 47) . This limitation is most likely due to some intrinsic properties of the intracellular lifestyle of Salmonella. During its intracellular stage, Salmonella remains within a membrane-bound compartment (13) . Therefore, heterologous antigens expressed in Salmonella do not efficiently reach the cytosol and subsequently the proteosome, a prerequisite for efficient stimulation of CD8 ϩ T-cell responses. Since efficient protection against some microorganisms (e.g., viral and certain parasitic and bacterial pathogens) requires this type of immune response, this limitation hampers the use of Salmonella as a "universal" vaccine platform.
We have used a Salmonella type III secretion system (TTSS) encoded in Salmonella pathogenicity island 1 (SPI-1) as an antigen delivery system to overcome this limitation (39) . Type III protein secretion systems have the capacity to deliver into the host cell cytosol a battery of bacterial proteins that can modulate host cell functions to increase pathogen survival and replication (14) . Proteins destined to travel in this secretion pathway possess discrete secretion signals that target them to the secretion machine and subsequently to host cells (7) . When fused to heterologous proteins, these signals can mediate delivery into the cytosol of eukaryotic cells (42) . We have adapted this system to construct avirulent S. enterica serovar Typhimurium strains expressing chimeric proteins consisting of the secretion and translocation signals of Salmonella type III secreted proteins (e.g., SopE or SptP) fused to different MHC class I epitopes from different pathogens (11, 39, 41) . These strains were able to induce CD8 ϩ T-cell responses directed to the heterologous proteins, which in some cases were able to confer protection in animal models of infection (11, 24, 39, 41) .
Previous studies in which the TTSS was used as an antigen delivery vehicle were carried out with either discrete epitopes or small portions of the heterologous proteins fused to the type III secretion (TTS) signals (11, 24, 39, 41) . However, efficient protection in most cases requires delivery of a larger repertoire of epitopes contained in larger polypeptides (8) . Although size per se is not an impediment for type III secretion (proteins that are vastly different sizes can be secreted by this machine), it is clear that there are proteins or protein motifs that are not amenable to secretion through this pathway (1, 30) . Since unfolding is a prerequisite for type III secretion, proteins with domains that have high intrinsic stability cannot be unfolded by the TTSS-associated ATPase and therefore cannot be secreted (1) . Therefore, if such a domain was present within a polypeptide relevant for vaccine development, it would hamper its delivery via the type III secretion pathway. We have been using the S. enterica serovar Typhimurium SPI-1 TTSS to construct a vaccine against human immune deficiency virus (HIV) (11) . Using the highly related simian immune deficiency virus (SIV) as a model, we have demonstrated that the S. enterica serovar Typhimurium SPI-1 TTSS can deliver a region of the viral Gag protein containing a MamuA-*01 epitope and prime mucosal antigen-specific CD8
ϩ T-cell immune responses in inoculated rhesus macaques (11) . However, construction of an effective HIV vaccine will require delivery of the entire Gag protein and presumably other viral proteins. In this paper, we describe construction of an S. enterica serovar Typhimurium vaccine strain that is capable of delivering via its SPI-1-TTSS the entire HIV and SIV Gag proteins, as well as a polypeptide made of sequences derived from the Rev, Tat, and Nef viral proteins. Construction of this strain required specific engineering of these viral proteins as the wild-type forms are not amenable to type III secretion. The strategy described in this study can be utilized to render any protein of interest permissive to type III secretion for vaccine construction.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The attenuated S. enterica serovar Typhimurium ⌬phoP ⌬phoQ (16) and ⌬asd (17) strains have been described previously and were grown in L broth containing 0.3 M sodium chloride at 37°C under conditions that stimulate expression of the SPI-1 TTSS (15) . When required, ampicillin was added at a final concentration of 100 g/ml. The growth characteristics of all strains used in these studies were indistinguishable.
Plasmid construction. Plasmid constructs expressing fusions between the secretion and translocation signals of the SPI-1 TTSS effector protein SopE or SptP (28, 29) and different segments of the SIV or HIV-1 protein Gag, Rev, Tat, or Nef were constructed using standard recombinant DNA techniques in lowcopy-number plasmid pWSK30 (46) . The adenovirus epitope M45 (34) and the H-2 b -restricted influenza virus nucleoprotein epitope NP 366-374 (FluNP) (38) were included between the SopE and viral sequences to enable detection of the chimeric proteins and assaying of antigen presentation in murine reporter cells, respectively. In all cases, expression of the constructs was driven by the sopE promoter. Plasmids were introduced into the S. enterica serovar Typhimurium strains by electroporation.
Type III protein secretion assay. Analysis of bacterial culture supernatant proteins was carried out by Western immunoblotting as previously described (25) , using a monoclonal antibody that recognized the M45 epitope present in the different constructs.
Antigen presentation assay. RMA cells (C57BL/6J mouse lymphoma) (9) were used as antigen-presenting cells (APCs) after infection with S. enterica serovar Typhimurium strains grown as described elsewhere (39) . About 3 ϫ 10 8 bacterial CFU was used to infect 10 7 APCs in 1 ml of Dulbecco's modified Eagle's medium at 37°C for 3 h. APCs subjected to the different procedures were washed, incubated for 1 h in Dulbecco's modified Eagle's medium containing gentamicin at a concentration of 100 g/ml, and distributed in quadruplicate 100-l cultures in 96-well plates containing 2 ϫ 10 5 APCs each. Influenza NP-specific T-cell hybridoma 12.164 (2 ϫ 10 5 cells) (9) was added to the treated RMA cell cultures. Culture medium was collected after incubation for 40 h at 37°C to determine the interleukin-2 (IL-2) concentration by a capture enzyme-linked immunosorbent assay (ELISA) (Pharmingen). Addition of the influenza NP peptide and addition of an irrelevant peptide from the lymphocytic choriomeningitis virus nucleoprotein (1 M) served as positive and negative controls, respectively. All bacterial strains used in these studies invaded RMA cells at the same levels.
Animal immunization. Groups of BALB/c female mice (eight mice per category) were fasted for 4 h before oral inoculation by stomach gavage of ϳ10 8 ⌬phoP ⌬phoQ S. enterica serovar Typhimurium cells expressing wild-type or TTS-optimized HIV Gag fused to the secretion and translocation signals of SopE or carrying the vector control. Four weeks after the first inoculation, animals were boosted by administering intraperitoneally ϳ10 4 ⌬asd S. enterica serovar Typhimurium cells carrying the same plasmids. The latter strain was used because it is severely attenuated and therefore can be administered intraperitoneally safely.
Measurement of Gag-specific CD8 ؉ T-cell responses in vaccinated mice by tetramer staining and flow cytometric analysis. Five days after boosting, immunized mice were sacrificed by CO 2 intoxication, and the spleens were removed. Splenocytes were isolated by forcing the spleens through a metal strainer with a 1-mm 2 mesh. Erythrocytes were lysed in buffer (pH 7.4) containing 0.15 M NH 4 Cl and 1 mM NaHCO 3 . Splenocytes were resuspended in phosphate-buffered saline containing 0.5% bovine serum albumin and 0.02% NaN 3 . Cells (ϳ5 ϫ 10 6 cells) were placed in a V-bottom 96-well plate for staining with streptavidin-APC-conjugated tetramers (obtained from the National Institutes of Health MHC Tetramer Core Facility, Emory University Vaccine Center) directed to an MHC H-2K d immunodominant Gag epitope (N-AMQMLKETI-C) (32) along with phycoerythrin-conjugated anti-CD62L and fluorescein isothiocyanate-conjugated anti-CD8a antibodies, using standard procedures. Stained cells were analyzed with a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, Calif.), and the flow cyometric profile was analyzed using the FlowJo software (Tree Star, Inc., San Carlos, Calif.).
RESULTS AND DISCUSSION
Identification of regions of SIV and HIV Gag that interfere with type III secretion. Protection against HIV is thought to require robust CD8 ϩ T-cell responses to viral protein antigens (35, 37) . SIV is the best model to study HIV pathogenesis and immunity because (i) it is highly related to HIV; (ii) SIV infections in primate animal models closely resembles HIV infections; and (iii) the parameters of protection are thought to be similar for the two diseases (20, 23) . We have previously shown that a chimeric protein composed of the secretion and translocation signals of the type III secreted protein SopE fused to the first 284 amino acids of the SIV Gag protein (SopE 1-104 SIV-Gag 4-284 ) was secreted efficiently via the SPI-1 TTSS and was able to prime CD8 ϩ T-cell responses when it was delivered by a Salmonella vaccine strain in inoculated rhesus macaques (11) . However, efficient protection most likely requires stimulation of responses against the entire SIV Gag protein, as well as other viral antigens. We therefore examined the ability of an S. enterica serovar Typhimurium vaccine strain to secrete a chimeric protein composed of fulllength SIV Gag fused to the secretion and translocation signals of SopE (28) and a class I-restricted T-cell reporter epitope consisting of residues 366 through 374 from the influenza virus nucleoprotein (SopE SIV-Gag ) (38) . Although SopE SIV-Gag 4-507 was efficiently expressed by S. enterica serovar Typhimurium, the chimeric protein was not secreted into cultured supernatants of the vaccine strain (Fig. 1A) . Consistent with the inability of this protein to be secreted by the SPI-1 TTSS, APCs infected with the S. enterica serovar Typhimurium strain expressing SopE SIV-Gag 4-507 did not present the FluNP 366-374 reporter epitope of the chimeric protein to a class I antigenpresenting pathway, as demonstrated using a reporter T-cell hybridoma (Fig. 1B) . The inability of SopE to drive the secretion and translocation of SIV-Gag suggested that some region(s) of this protein interferes with type III secretion. In an attempt to identify the region of SIV Gag responsible for its secretion incompetence, we constructed a series of deletions of the chimeric protein and tested them to determine whether they could be secreted via the SPI-1 TTSS. As previously shown (11), SopE 1-104 SIV-Gag 4-284 , which encompasses the amino-terminal half of SIV Gag, was efficiently secreted by the SPI-1 TTSS (Fig. 1A) and was delivered to the class I antigenpresenting pathway (Fig. 1B) . These results indicated that the interfering region must be located within the carboxyl-terminal half of SIV Gag. Consistent with this hypothesis, a chimeric protein composed of SopE 1-104 SIV-Gag 267-507 was poorly secreted (Fig. 1 A) and was inefficient at stimulating class I-restricted T-cell responses in vitro when it was expressed by an S. enterica serovar Typhimurium vaccine strain (Fig. 1B) (Fig. 1A) . In addition, the deletion mutant was efficiently delivered to a class I antigenpresenting pathway of antigen-presenting cells infected with an S. enterica serovar Typhimurium strain expressing SopE SIVGag ⌬392-425 (Fig. 1B) . Taken together, these results indicate that removal of its Zn finger domains renders SIV Gag permissive for type III secretion and delivery to the class I antigen-presenting pathway. We then examined the ability of the S. enterica serovar Typhimurium SPI-1 TTSS to secrete HIV Gag when it was fused to the secretion and translocation signals of SopE. Consistent with the results obtained with SIV Gag, a chimeric protein consisting of the secretion and translocation signals of SopE fused to the FluNP 366-374 reporter T-cell epitope and full-length HIV Gag (SopE 1-104 HIV-Gag 4-501 ) was not secreted by the S. enterica serovar Typhimurium SPI-1 TTSS, although it was readily detected in bacterial lysates ( Fig. 2A) . In addition, an S. enterica serovar Typhimurium strain expressing SopE 1-104 HIV-Gag 4-501 did not deliver the chimeric protein into a class I antigen-presenting pathway of infected APCs. These results indicated that similar to SIV Gag, a region of HIV Gag prevents delivery of the protein through the SPI-1 TTSS. We then investigated whether, similar to SIV Gag, removal of the Zn finger domains rendered HIV Gag permissive for type III secretion. We found that removal of residues 392 through 426, which contain the two Zn fingers, rendered HIV Gag permissive for SopE 1-104 -mediated secretion ( Fig. 2A ) and for delivery to the class I antigen-presenting pathway (Fig.  2B) . Taken together, these results indicate that removal of discrete domains that may interfere with the TTSS can render a nonpermissive protein competent for engagement by the type III secretion machinery. Since class I-restricted epitopes tend to be linear and not influenced by the tertiary structure of the protein from which they are derived (31), removal of a small discrete region of Gag is not likely to affect its immunogenicity.
Comparison of the abilities of the secretion and translocation signals of SopE and SptP to mediate delivery of heterologous proteins to a class I antigen-presenting pathway. In previous studies, we have shown that the secretion and translocation signals of both SptP and SopE can mediate the delivery of heterologous peptides to the class I antigen-presenting pathway (11, 39) . However, the relative efficiencies of delivery of these different signals have not been specifically compared. Since these proteins utilize different chaperones for targeting to the secretion machinery (12, 28) , it is possible that the secretion domains may mediate heterologous secretion with different efficiencies. We therefore compared the abilities of the secretion and translocation signals of SopE and SptP to deliver different SIV Gag constructs to the class I antigenpresenting pathway. Delivery to this antigen-presenting path- OPTIMIZING TYPE III SECRETION FOR VACCINE DEVELOPMENTway requires secretion from the bacterial cell, as well as translocation into and processing within antigen-presenting cells. Therefore, antigen presentation probes the ability of a given secretion and translocation signal to perform all the functions relevant for heterologous antigen delivery. To carry out the comparison, we used SIV Gag constructs that showed different efficiencies of secretion when they were fused to the secretion and translocation signals of SopE (Fig. 1) . We fused the same Gag regions of these constructs to the SptP secretion and translocation signals and the FluNP 366-374 reporter T-cell epitope and compared the abilities of the different chimeras to be delivered to a class I antigen-presenting pathway. We found that the secretion and translocation signals of SopE were consistently more efficient at delivering the different Gag constructs to the class I antigen-presenting pathway than were the signals derived from SptP (Table 1) . In all cases, Gag constructs that were not secreted and delivered to the class I antigen-presenting pathway by the SopE signals were also not delivered to the class I pathway by the SptP signals. In conclusion, at least for these Gag constructs, the secretion signals derived from SopE are more effective at mediating delivery of heterologous proteins to a class I antigen-presenting pathway.
Comparison of the immunogenicities of optimized and wildtype Gag proteins when they are delivered by the S. enterica serovar Typhimurium SPI-1 TTSS in infected mice. To investigate whether the optimization of heterologous protein secretion via the TTSS results in increased immunogenicity, we compared using a mouse model the immunogenicities of avirulent S. enterica serovar Typhimurium strains expressing wild-type and TTS-optimized HIV Gag fused to the secretion and translocation signals of SopE (SopE HIV-Gag 4-501 and SopE HIV-Gag
⌬392-426
, respectively). Mice were immunized orally with an avirulent ⌬phoP ⌬phoQ S. enterica serovar Typhimurium strain expressing SopE 1-104 HIV-Gag 4-501 or SopE 1-104 HIVGag ⌬392-426 or carrying the vector control. Four weeks after oral immunization, animals were boosted with an intraperitoneal dose of avirulent ⌬asd S. enterica serovar Typhimurium strains expressing the same constructs. One week after the boost, animals were sacrificed, and the levels of HIV Gagspecific CD8 ϩ T cells in the spleen were quantified by tetramer staining and flow cytometry. The mice immunized with S. enterica serovar Typhimurium expressing the optimized HIV Gag protein developed significantly larger numbers of Gagspecific CD8 ϩ T cells than the mice immunized with the strains expressing the wild-type form of Gag or the empty vector control developed (Fig. 3) . Consistent with the in vitro studies, these results demonstrate that the optimization of proteins for TTSS-mediated delivery results in improved immunogenicity in vivo.
Optimization of SIV and HIV Rev, Tat, and Nef for type III secretion. Optimal protection against a given pathogen is likely to require immunization with several antigens from the pathogen. Indeed, it is often the case that the best protection is obtained using attenuated live forms of the pathogen that the vaccine is intended to protect against (8, 22) . This is likely due to the fact that efficient protection is likely to require the ability to induce complex immune responses directed to several antigens from the pathogen. For example, in the case of SIV infections, a model for HIV infections, it has been shown that attenuated forms of the virus confer probably the best protection against experimental challenge (26) . However, due to safety concerns, the use of attenuated HIV as a vaccine is considered to be impractical. In an attempt to construct a vaccine able to induce an immune response to as many HIV (or model virus SIV) antigens as possible without safety concerns, we investigated delivery of the viral proteins Rev, Tat, and Nef via the S. enterica serovar Typhimurium SPI-1 TTSS. Splenocytes from immunized animals were examined by flow cytometry to determine the levels of HIV Gag-specific CD8 ϩ T cells. Open circles represent individual mice, and the values are the percentages of CD8 T cells that are tetramer specific for the Gag epitope. The horizontal bars indicate the means. The differences between the levels of Gag-specific CD8 T cells in animals immunized with the optimized Gag and the levels of Gag-specific CD8 T cells in animals immunized with the nonoptimized Gag and between the levels of Gag-specific CD8 T cells in animals immunized with the optimized Gag and the levels of Gag-specific CD8 T cells in animals immunized with the vector control were statistically significant (P ϭ 0.038 and 0.0001, respectively). We fused each of the open reading frames of these proteins to the secretion and translocation signals of SopE (SopE ) and the FluNP 366-374 reporter T-cell epitope and examined the type III secretion and MHC class I antigen presentation of the chimeric proteins. In all cases we used a mutant form of Nef (Nef ⌬239-240 ), which has been shown to lack the ability to down regulate the expression of MHC class I molecules (6) . Although SIV Nef was secreted via the SPI-1 TTSS, Rev and Tat were not (data not shown). In close correlation with type III secretion, chimeric SopE 1-104 -SIV-Nef was efficiently delivered to a class I antigen presentation pathway in APCs infected with S. enterica serovar Typhimurium expressing this protein, while SIV Rev and SIV Tat were not (Fig. 4A) .
We then carried out a detail deletion analysis to identify the regions of SIV Rev and SIV Tat that interfere with type III secretion. Chimeric proteins containing different portions of the carboxyl terminus of Rev fused to the secretion and translocation signals of SopE (SopE ) were efficiently secreted via the SPI-1 TTSS (data not shown) and delivered to the class I antigen-presenting pathway (Fig. 4B) . In contrast, the amino-terminal half of Rev was not secreted when it was fused to SopE (data not shown) or delivered to the class I antigen-presenting pathway (Fig. 4B) . These results indicated that the region of Rev interfering with TTS is located within its amino terminus. Within this region of Rev there is a helix-turn-helix domain involved in RNA binding (5) . We hypothesized that destabilization of this domain may render Rev more permissive for secretion. Indeed, removal of amino acids 39 to 46 of Rev, which encompass its RNA-binding domain, rendered this protein permissive for TTS (data not shown) and delivery into the class I antigen-presenting pathway (Fig. 4B) .
Although delivery of different antigens by the S. enterica serovar Typhimurium TTSS could be achieved by administration of a mixture of bacteria expressing different chimeric proteins, it would be advantageous to minimize the number of strains used in a potential vaccine. Since Rev, Tat, and Nef are small polypeptides, we reasoned that they could be engineered so that they are delivered simultaneously as a single polypeptide fused to a type III secretion signal. We first constructed a plasmid expressing a chimeric protein consisting of the secretion and translocation signals of SopE (SopE- ) fused to the FluNP 366-374 reporter T-cell epitope and to a polyprotein made of wild-type and TTS-optimized SIV Rev (SIV-Rev ⌬39-46 ), SIV Tat (SIV-Tat 1-130 ), and SIV Nef (SIV-Nef ). The resulting chimera containing wild-type Rev was not secreted by the TTSS (Fig. 4C) or delivered into the class I antigen-presenting pathway (Fig. 4D) . In contrast, the chimera containing the TTS-optimized Rev was secreted into culture supernatants (Fig. 4C) and delivered into the class I antigen-presenting pathway (Fig. 4D) , although with reduced efficiency. Since SIV Nef is efficiently secreted by the SPI-1 TTSS (Fig. 1A) , a series of deletions were introduced into SIV Tat to identify the regions that interfere with secretion of the chimeric protein. Two regions of Tat were targeted: a cysteine-rich region that coordinates the binding of two Zn atoms (amino acids 56 to 66) and a basic region proposed to bind RNA (amino acids 80 to 88) (4). Removal of one of these domains improved secretion and antigen presentation, and removal of both regions improved secretion and antigen presentation even further ( Fig.  4C and D) . We then used the information gained through the TTSS optimization of SIV Rev, Tat, and Nef to construct a similar polyprotein containing the HIV homologs. It has been proposed previously that regions located immediately adjacent to the secretion and translocation signals of type III-secreted proteins may play an important role during the unfolding process prior to secretion (43, 44) . We therefore placed HIV Nef immediately adjacent to the secretion and translocation signals of SopE since SIV Nef was found to be permissive for secretion. Indeed, placing HIV Nef immediately before the secretion-incompetent HIV protein Rev resulted in a chimeric protein that was competent for secretion and antigen presentation (Fig. 5A and B and data not shown) . In an effort to further optimize the type III secretion of the HIV Nef-Rev polypeptide, we introduced deletions into the regions of HIV Rev that were shown to be deleterious for secretion in the SIV homolog. As shown in Fig. 5 , introduction of the optimizing deletion into Rev did not significantly improve the secretion and antigen presentation of the HIV Nef-Rev chimera. Addition of Tat to the Nef-Rev polyprotein resulted in a chimeric protein that, unlike the SIV Rev-Tat-Nef polyprotein (Fig. 4C and D) , was secreted and delivered to the class I antigen-presenting pathway ( Fig. 5A and B) . Disruption of the cysteine-rich region of Tat by changing five cysteines to either alanine or glycine (the original sequence, CKKCCFHCQVC, was changed to GKKG AFHAQVG) or by introducing a deletion did not significantly improve the secretion of the polyprotein (Fig. 5A and B) . In summary, placing the TTS-competent protein Nef immediately adjacent to the secretion signal significantly improved the efficiency of delivery by the SPI-1 TTSS of the HIV Nef-Rev-Tat chimera. These results indicate that addition of a protein domain that easily unfolds may be a general strategy for optimizing delivery of heterologous proteins via the TTSS.
Concluding remarks. In this study, we demonstrated the feasibility of an approach to render heterologous proteins that are nonpermisive for secretion via the S. enterica serovar Typhimurium SPI-1 TTSS amenable to transit through this pathway by introducing discrete small changes within interfering domains or by placing domains more prone to unfolding immediately adjacent to the secretion signal. We used this approach to optimize the secretion of several SIV and HIV proteins. Optimization of proteins for delivery through the type III secretion pathway should allow the use of this system for construction of vaccines against any microbial pathogen.
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